Live Breaking News & Updates on Risankizumab

Stay updated with breaking news from Risankizumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

This interview with Bunick featured a discussion of his team’s recent data comparing anti-IL-23 biologics, epitopes, and comparisons with risankizumab. ....

Christopher Bunick , Yale School Of Medicine , Structural Basis , Long Term Efficacy , Yale School , Il 23 ,

Risankizumab Effective Through 100 Weeks in Improving Signs, Symptoms of Psoriatic Arthritis

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.
....

South Australia , Monash University Department , American College Of Rheumatology , Monash University , American College , Active Psoriatic Arthritis , Week Results , Rheumatol Ther , Psoriatic Arthritis , 100 Weeks ,

Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA

Blauvelt discusses the impetus for his phase 2 trial looking at the ability to mitigate pivotal psoriasis memory T cells with risankizumab. ....

San Diego , United States , Andrew Blauvelt , American Academy Of Dermatology , Oregon Medical Research Center , American Academy , Psoriasis Area Severity Index , Aad 2024 , Sandy Blauvelt ,

Marla Dubinsky, MD: Clinical Outcomes with Risankizumab Versus Ustekinumab in SEQUENCE

Dubinsky discusses findings from a post-hoc analysis of the head-to-head SEQUENCE trial of risankizumab versus ustekinumab in patients with Crohn disease refractory to anti-TNF therapy. ....

Marla Dubinsky , Colitis Organisation Congress , Drug Administration , European Crohn , Mount Sinai Kravis Children , United European Gastroenterology Week , Inflammatory Bowel Disease , Crohn X27s Disease , Clinical Remission , Clinical Outcomes , Abdominal Pain ,

Sequence Study of Risankizumab vs Ustekinumab in CD

David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment. ....

Marla Dubinsky , David Rubin , Miguel Regueiro , Remo Panaccione , Sara Horst , Crohn X27s Disease , Il 12 , Il 23 , First Line Treatment ,